During the visit, attendees will receive a detailed overview of Optiscan’s strategic direction, commercialisation progress, and key milestones across its three core markets:
• Medical – advancing real-time digital pathology and precision surgery
• Veterinary – expanding imaging capabilities into animal healthcare
• Life Sciences – enabling high-resolution live-cell imaging in preclinical research
The visit will include live demonstrations of Optiscan’s expanding product range, including:
• InVue™ – a next-generation system for surgical applications
• InForm™ – digital pathology technology
• InVivage® – an intra-oral endomicroscope
• ViewnVivo® – a high-resolution imaging system for real-time life sciences research
In addition, Optiscan will provide an overview of its Software-as-a-Medical-Device (SaMD) initiatives, particularly in telepathology and AI-driven diagnostics, which form a key part of the Company’s future growth strategy.
The event will include a presentation from Optiscan’s Chief Executive Officer, Dr Camile Farah, followed by a Q&A session and tour of the facilities.
To read the announcement, please click here
About us:
About Optiscan Imaging
Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.
Using a revolutionary "tissue contact" method, Optiscan’s patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.
The global addressable market for Optiscan’s medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.
To learn more about Optiscan, visit www.optiscan.com
Contact details:
Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
+61 3 9538 3333
ceo@optiscan.com
Media & Investor Enquiries
The Capital Network
Julia Maguire
+61 2 7257 7338
julia@thecapitalnetwork.com.au
Initial contract in support of a material feasibility program for BAE Systems.